Press Releases

Huateng Pharma Develops CAS NO.156-83-2 (Minoxidil Intermediate) Against Hair Loss

Aug 9, 2023, 09:03 AM by
About Huateng Pharma Huateng Pharma is a global provider in contract development and manufacturing for intermediates. With our focus on operational excellence, and the integration of manufacturing operations with EHS, quality assurance, quality control, regulatory, supply chain management and project management, we can manufacture, scale-up and supply high-quality intermediates and APIs from our China facility. Contact us Hunan Huateng Pharmaceutical Co. Ltd. Address: Lugu Business Plaza E1, Yuelu District, Changsha City, Hunan Province, China Manufacturing Base: Tongguan Kiln, Wangcheng district, Changsha, Hunan, China Email: sales@huatengusa.com Website: https://us.huatengsci.com Zip code: 410205 Telephone: +86 731 89916275 Fax: +86 0731-82251112-818

Minoxidil is a potassium channel opener developed in the 1970s. It was initially used for refractory hypertension. Due to the observed side effect of hypertrichosis, it was gradually used to treat hair loss. Huateng Pharma is a one-stop contract development and manufacturing organization (CDMO) for pharmaceutical intermediates from clinical supply to commercial scale. It can supply large quantities of 2,4-Diamino-6-chloropyrimidine (CAS NO.156-83-2), an intermediate of Minoxidil for the treatment of hair loss.

Minoxidil, as the most commonly used drug for treating hair loss, has been widely used, and its main effect is to treat alopecia areata and seborrheic alopecia (ie, male pattern hair loss).

Minoxidil can increase local blood supply, stimulate the proliferation and differentiation of hair follicle epithelial cells, so as to promote hair growth and achieve the purpose of treating hair loss. Minoxidil is the only topical drug approved by the US FDA for the treatment of hair loss. Its effect in the treatment of seborrheic alopecia is beyond doubt.

The "Anti-Hair Loss Industry Market In-Depth Analysis Report 2023" predicts that China's hair health industry will grow at an annual rate of 260% in the next 10 years. The scale of the domestic hair loss drug treatment market is expected to reach 15.5 billion yuan in 2031, and the compound annual growth rate from 2021 to 2031 is expected to reach 32%. From the perspective of the global market, the global hair loss market will reach at least 8.81 billion US dollars in 2021, and it is expected to grow to 13.44 billion US dollars (about 89.6 billion yuan) in 2026, with an average annual compound growth rate of 8.8%.

“In response to this trend, our management decides to add a new product line, providing Minoxidil intermediate (2,4-Diamino-6-chloropyrimidine, CAS NO.156-83-2) with high purity and the most reasonable price,” says the Marketing Chief of Huateng Pharma. ”Previously, we have already been a trust-worthy CDMO for pharmaceutical intermediates, offering custom synthesis and scale-up services for many years. We will continue to provide customers with high quality and high standard products according to market demand.”

Huateng Pharma is a one-stop contract development and manufacturing organization (CDMO) for pharmaceutical intermediates from clinical supply to commercial scale. We have a 34,000 square meter manufacturing site with advanced design concept of intelligent manufacturing, which can realize the integration of the production process and accomplish the complete transformation of lab scale - pilot plant - large-scale commercial production.